# Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism

> **NCT02898051** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 370 (actual)

## Conditions studied

- Neoplasms
- Venous Thromboembolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02898051
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-08
- **Primary completion:** 2017-10
- **Final completion:** 2018-01
- **Target enrollment:** 370 (ACTUAL)
- **Last updated:** 2017-10-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02898051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02898051, "Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT02898051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*